Alectinib capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Alecensa
- Company
- Genentech, Inc.
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- US indications cover adults with ALK-positive metastatic NSCLC, and adjuvant treatment after resection of ALK-positive NSCLC when the tumor is at least 4 cm or lymph nodes are involved. ALK status must be established by an approved test.
- Indication source and scope
- US label; DailyMed updated 21 August 2026. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval details and current availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
- Alecensa — US prescribing information
Official prescribing information · US label; DailyMed updated 21 August 2026
English primary source opened on 2 November 2026. The summary lists selected US indications, not the complete current Chinese approved scope.
Evidence reviewed:
Open the interactive record, public price references and discussions